/
Other
Nab-Paclitaxel
9
Pipeline Programs↗
9
Active Trials↗
10
Companies Involved↗
Nab-paclitaxel is an early-stage landscape with 9 programs across 10 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 29
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
6 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
33
clinical trials
Completed14 · 42%
Unknown status6 · 18%
Recruiting6 · 18%
Terminated4 · 12%
Not yet recruiting3 · 9%
Clinical Trials
Trial Activity
33 trials
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06632405·60 enrolled
Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC
Not yet recruiting·—·Phase 2·NCT07103447·54 enrolled
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Completed·—·Phase 2·NCT02716038·39 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)